

Support of GE Healthcare to quicken CBMG's Cell Therapy Manufacturing

22 January 2018 | News

GE supports CBMG in its aim to speed up manufacturing timelines for its CAR T-cell therapy clinical trials and future commercialization



CBMG is Cellular Biomedicine Group which develops proprietary cell therapies for the treatment of cancer and degenerative diseases.

This biopharmaceutical firm has announced its plan to configure part of its facility in Shanghai with GE Healthcare's FlexFactory™ platform, which will be designed to speed up manufacturing timelines for its cell therapy clinical trials and commercial launch.

To overcome the challenges of cell therapy manufacturing process, GE Healthcare has developed FlexFactory for cell therapy, a scalable, semi-automated end-to-end platform.

The complete process of getting a lab ready for optimized industrial-scale manufacturing would typically take a cell therapy manufacturer over 18 months.

FlexFactory can reduce this time by up to 50 percent, ultimately accelerating time to market and enabling clinicians to deliver therapies to patients sooner.

CBMG plans to use its FlexFactory to speed up its timelines for commercializing its CAR T-cell therapies, targeting various blood and solid tumor cancers.

Through its collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM), a leader in developing and commercializing regenerative medicine technologies and cell and gene therapies, GE Healthcare is providing CBMG with process development services.

GE and CCRM will support CBMG in increasing process efficiency by establishing a robust process development effort focused on simplifying, integrating and automating the manufacturing workflow.